Neurocrine to acquire Soleno in $2.9B rare disease deal

Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion in cash, the companies announced, marking a major expansion into treatments for metabolic disorders.

Under the deal, Neurocrine will pay $53 per share, about a 34% premium to Soleno’s last closing price—highlighting strong investor interest in the rare disease space, News.Az reports, citing Reuters.

The acquisition gives Neurocrine access to Vykat XR, the first U.S.-approved treatment for hyperphagia linked to Prader-Willi syndrome.

Hyperphagia, an extreme, persistent feeling of hunger, is the defining symptom of the condition and can lead to severe obesity, along with physical, cognitive, and behavioral complications.

News.Az 

By Aysel Mammadzada